Want to see HK:2185 full AI Analyst Report?
2185 Stock Chart & Stats
HK$5.71
HK$0.03(1.94%)
At close: 4:00 PM EST
HK$5.71
HK$0.03(1.94%)
Day’s Range― - ―
52-Week RangeHK$1.28 - HK$9.10
Previous CloseN/A
Volume27.00K
Average Volume (3M)73.35K
Market Cap
HK$317.66M
Enterprise ValueHK$734.25M
Total Cash (Recent Filing)HK$237.83M
Total Debt (Recent Filing)HK$180.43M
Price to Earnings (P/E)―
Beta2.26
Next Earnings
Mar 26, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding235,703,410
10 Day Avg. Volume37,390
30 Day Avg. Volume73,353
Financial Highlights & Ratios
PEG Ratio0.84
Price to Book (P/B)2.91
Price to Sales (P/S)28.92
P/FCF Ratio-17.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)HK$2.07B
Bulls Say, Bears Say
Bulls Say
2025 Revenue ReboundThe 2025 revenue rebound indicates renewed commercial activity after a very weak base and provides a larger platform for future operating leverage. Although profitability remains unproven, sustained revenue expansion could improve the company’s ability to absorb fixed costs and support broader adoption of its products.
Very Low LeverageMinimal leverage provides financial flexibility because the company faces limited debt-service pressure and is less exposed to refinancing stress. This balance-sheet strength can preserve strategic options during continued development and commercialization, even though ongoing losses may gradually reduce the equity cushion.
Focused Regenerative Medicine PlatformA focused business model centered on regenerative medicine, tissue engineering, and clinical implantable products gives the company a defined technology and commercialization direction. Products used in clinical settings can support longer development and adoption cycles, creating a basis for durable business growth if execution improves.
Bears Say
Deep And Persistent LossesNegative gross profit and substantial operating losses show that the current revenue base does not yet cover the economics of the business. Continued losses reduce financial resilience, constrain reinvestment, and indicate that the company has not demonstrated a sustainable profitable revenue model over the medium term.
Ongoing Cash BurnPersistent negative operating and free cash flow means the company is not funding its activities internally and must rely on external funding capacity. Continued cash burn can limit investment flexibility, increase financing dependence, and create pressure to secure capital before commercial progress translates into self-sustaining operations.
Eroding Equity And Negative ReturnsDeclining equity reflects the cumulative effect of ongoing losses and weak capital productivity. Consistently negative returns on equity show that invested capital is not currently generating profits, while further losses could erode the balance-sheet cushion despite the company’s presently low leverage.
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H News
2185 FAQ
What was Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s price range in the past 12 months?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H lowest stock price was HK$1.28 and its highest was HK$9.10 in the past 12 months.
What is Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s market cap?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s market cap is HK$317.66M.
When is Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s upcoming earnings report date?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s upcoming earnings report date is Mar 26, 2027 which is in 164 days.
How were Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s earnings last quarter?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H released its earnings results on Aug 26, 2026. The company reported -HK$0.153 earnings per share for the quarter.
Is Shanghai Bio-Heart Biological Technology Co., Ltd. Class H overvalued?
According to Wall Street analysts Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s price is currently Overvalued.
Does Shanghai Bio-Heart Biological Technology Co., Ltd. Class H pay dividends?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H does not currently pay dividends.
What is Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s EPS estimate?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shanghai Bio-Heart Biological Technology Co., Ltd. Class H have?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H has 235,703,410 shares outstanding.
What happened to Shanghai Bio-Heart Biological Technology Co., Ltd. Class H’s price movement after its last earnings report?
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H reported an EPS of -HK$0.153 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Shanghai Bio-Heart Biological Technology Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2185
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-83.88%
12-Months-Change
Fundamentals
Return on Equity
-17.76%
Trailing 12-Months
Asset Growth
-5.02%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
Based in the People's Republic of China, Shanghai Bio-heart Biological Technology Co., Ltd. is a medical technology firm specializing in interventional cardiovascular devices. Its core business revolves around delivering bioresorbable scaffolds (BRS) and renal denervation (RDN) therapies to address conditions like coronary artery diseases and persistent, uncontrolled high blood pressure. The company's product pipeline features Bioheart, a BRS system designed for percutaneous coronary interventions for coronary artery disease; Iberis 2nd, a multi-electrode RDN product candidate; and a sirolimus drug-eluting balloon catheter intended for managing in-stent restenosis. Furthermore, the company has partnered with Terumo (China) Investment Co., Ltd. to conduct clinical trials for Iberis 2nd. Shanghai Bio-heart Biological Technology Co., Ltd. was established in 2014 and maintains its headquarters in Shanghai, China.
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H (2185) Earnings & Revenues
Technical Analysis
CARsgen Therapeutics Holdings Ltd.
―
Mabpharm Limited
―
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―
Wuhan YZY Biopharma Co., Ltd. Class H
―
Sunho Biologics,Inc.
―